Matricelf Ltd. Logo

Matricelf Ltd.

Develops autologous, patient-specific tissue implants for regenerative medicine.

MTLF | TA

Overview

Corporate Details

ISIN(s):
IL0011767915
LEI:
Country:
Israel
Address:
3 Golda Meir Street, 7651713 Ness Zion

Description

Matricelf Ltd. is a preclinical-stage biotechnology company specializing in regenerative medicine and tissue engineering. The company develops a proprietary platform for creating fully autologous, patient-specific tissue implants. This technology combines a patient's induced Pluripotent Stem Cells (iPSCs) with a personalized, thermo-responsive hydrogel derived from their own extracellular matrix (ECM). The iPSCs are differentiated within this hydrogel to generate functional tissue. This autologous approach is designed to minimize the risk of immune rejection and provide a personalized, curative therapy. Matricelf's primary focus is on developing a one-time treatment for spinal cord injuries, aiming to bridge damaged tissue and restore lost function. The platform is also being explored for other conditions, including stroke, traumatic brain injury, and myocardial infarction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-08 20:40
COMPANY'S PRESENTATION
Hebrew (modern) 2.3 MB
2024-09-08 20:40
COMPANY'S PRESENTATION
Russian 42.8 KB
2024-03-27 15:30
INVESTORS PRESENTATION
English 2.7 MB
2024-03-27 15:30
INVESTORS PRESENTATION
Russian 43.3 KB
2023-02-14 16:31
Corporate Presentation - February2023
English 1.1 MB
2023-02-14 16:31
Corporate Presentation - February2023
Russian 42.7 KB
2022-03-16 10:59
INVESTORS PRESENTATION
English 2.7 MB
2022-03-16 10:59
INVESTORS PRESENTATION
Russian 41.6 KB
2021-06-17 18:14
Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker
Hebrew (modern) 256.5 KB
2021-06-14 14:20
Identifying Details of New Security: MATRICELF, MATRICELF.W1
Hebrew (modern) 177.2 KB

Automate Your Workflow. Get a real-time feed of all Matricelf Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matricelf Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matricelf Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Sds Optic Spolka Akcyjna Logo
Develops diagnostic solutions, custom antibodies, and optical coatings.
Poland
SDS
Seer, Inc. Logo
A life sciences company that develops products for proteomics research.
United States of America
SEER
Selvita S.A. Logo
Preclinical CRO offering integrated drug discovery and development services.
Poland
SLV
SensoDetect AB Logo
Develops AI decision-support solutions for mental illness diagnostics.
Sweden
SDET
Sensorion Logo
Clinical-stage biotech developing novel therapies for inner ear disorders and hearing loss.
France
ALSEN
Senti Biosciences, Inc. Logo
Clinical-stage biotech developing cell and gene therapies using a Gene Circuit platform.
United States of America
SNTI
SeouLinBioscienceCO.,LTD. Logo
A solutions provider for life sciences, supplying research reagents and equipment.
South Korea
038070
Septerna, Inc. Logo
Clinical-stage biotech developing oral small molecule medicines targeting GPCRs.
United States of America
SEPN
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Logo
A contract research organization providing comprehensive drug development services.
Japan
2395
Silence Therapeutics plc Logo
Clinical-stage biotech developing siRNA medicines to silence disease-causing genes.
United States of America
SLN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.